Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pyxis Oncology, Inc.

1.09
+0.03002.83%
Volume:508.26K
Turnover:563.74K
Market Cap:67.13M
PE:-0.82
High:1.16
Open:1.08
Low:1.06
Close:1.06
Loading ...

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

Zacks
·
22 Nov 2024

Pyxis Oncology Shares Slump After William Blair Downgrade

MT Newswires Live
·
22 Nov 2024

Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade

seekingalpha
·
21 Nov 2024

Pyxis Oncology Is Maintained at Outperform by RBC Capital

Dow Jones
·
21 Nov 2024

RBC ups Pyxis Oncology target, says buy shares on selloff

TIPRANKS
·
21 Nov 2024

William Blair Downgrades Pyxis Oncology to Market Perform

MT Newswires Live
·
21 Nov 2024

Pyxis Oncology Cut to Market Perform From Outperform by William Blair

Dow Jones
·
21 Nov 2024

Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Nov 2024

Pyxis Oncology reported ‘compelling’ cancer dataset, says H.C. Wainwright

TIPRANKS
·
21 Nov 2024

RBC Boosts Price Target on Pyxis Oncology to $10 From $7, Keeps Outperform, Speculative Risk

MT Newswires Live
·
21 Nov 2024

Pyxis Oncology downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
21 Nov 2024

Pyxis Oncology Inc : William Blair Cuts to Market Perform

THOMSON REUTERS
·
21 Nov 2024

U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target

Reuters
·
21 Nov 2024

Pyxis Oncology Reports Promising Phase 1 Trial Results

TIPRANKS
·
21 Nov 2024

Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck

TIPRANKS
·
21 Nov 2024

Pyxis Oncology Inc: Pyx-201 Generally Well-Tolerated With a Favorable Safety Profile

THOMSON REUTERS
·
21 Nov 2024

Pyxis Oncology Announces Favorable Preliminary Pyx-201 Clinical Phase 1 Part 1 Data

THOMSON REUTERS
·
21 Nov 2024

Stifel Nicolaus Remains a Buy on Pyxis Oncology (PYXS)

TIPRANKS
·
13 Nov 2024

RBC Capital Sticks to Its Buy Rating for Pyxis Oncology (PYXS)

TIPRANKS
·
13 Nov 2024

Pyxis Oncology Q3 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate

Benzinga
·
12 Nov 2024